

Before use please read the Instructions for Use, which contains information of significance for the patient regarding the product's use.

The Instructions for Use should be kept to be available again.

MedCare Intima HPV Stop Spray

DESCRIPTION OF MED CARE INTIMA HPV STOP SPRAY MEDICAL PRODUCT

An innovative medical product in the form of spray against HPV for the intimate body regions to protect against HPV virus penetration to the host's cell.

The components responsible for the essential performance of the product are tannin and iota-carrageenan.

The human papilloma viruses (HPV) comprise a large family (with over 150 types thus far discovered) of DNA viruses common within the population in both sexes.

The virus is transmitted sexually, it infects the skin and mucous membranes.

Globally, the human papilloma virus (HPV) causes over 5% of cancer cases, including all cases of cervical cancer and a worryingly increasing percentage of cases of the oral cavity and throat cancer.

To produce an infection, the virus must reach the host's cell and provide its DNA to the cell nucleus.

Normally functioning skin and mucous membrane constitute natural barriers for viruses.

INGREDIENTS

Purified water, caprylic/capric triglyceride, zinc oxide, propylene glycol, glycerin, stearic acid and polyglycerol diester, tannic acid, lactic acid, mixture of cetyl alcohol and stearyl alcohol, hexaglycerol and behenic acid ester, sodium benzoate, xanthan gum, carrageenan.

GENERAL INFORMATION AND INDICATIONS

This medical product is recommended for:

- thanks to its iota-carrageenan content as a physical barrier for the virus;
- protection of the ano-genital area as an agent intended for people with high risk of exposure of the intimate region exposure to pathogens, including HPV;
- thanks to tannin it prevents the spread of HPV from the intimate regions to other exposed areas such as epithelium in the oral cavity and throat;
- thanks to the presence of iota-carrageenan, to reduce the relapses following interventions, e.g. recurrence of warts caused by HPV following cryotherapy or surgical treatments.

MECHANISM OF ACTION OF THE MEDICAL PRODUCT

The mechanism of action of the medical product consists in creation of a physical barrier on the surface of the intimate regions. Iota-carrageenan contained in the product is responsible for the development of a barrier protecting against the binding of virus in the receptors of the host's cells and inhibiting release of the virus from infected cells. It constitutes a biological barrier preventing virus adherence and their penetration into the organism.

The created layer constitutes a mechanical barrier, and its components, such as tannin, inactivate the pathogens on the surface.

HOW TO USE

Wash the intimate regions and hands before using the product.
Spread the spray on the intimate regions directly before and after intercourse.
The spray can be used 3-4 times per day.

WARNINGS AND CONTRAINDICATIONS

Do not use in the case of sensitivity (allergy) to any of the product's ingredients.
If during use of the gel a burning sensation, itchiness or skin reddening occur, stop using the product and in when the symptoms have resolved consult a physician or pharmacist.
Use the product during pregnancy or breastfeeding after consultation with a physician or pharmacist.
Do not use during menstruation.
Avoid accidental contact of gel with eye mucosa.
Do not use after the expiry date.
Product to be used on the intimate regions.
Do not swallow!

STORAGE

Store the product in its original packaging.
Store in room temperature, i.e. 5-30°C.
Protect against light and sources of heat.
Keep out of reach and sight of children.
Do not use the product in the case of direct packaging damage.
Do not use after the expiry date provided on the packaging.

Product packaging contains

Spray 50 ml, Instructions for Use.




MANUFACTURER

LABORATOIRE L'IDEAL Parisien Sp. z o.o.
Ul. Ogrodowa 8, 32-064 Niegoszowice
tel./fax +48 12/ 283 88 60

DISTRIBUTOR:



MEDICAL DEVICE



Informacja na opakowaniu

Date of update IFU Edition 02 z dnia 15.02.2022